Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
Akero Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of transformative treatments for patients with NASH and other serious metabolic diseases with high unmet medical need. The Company's lead program AKR-001 is being evaluated in a Phase 2a clinical trial for the treatment of NASH. AKR-001 is an engineered human Fc-FGF21 fusion protein designed to harness the inherent benefits of an endogenous hormone called FGF21, with the potential to reduce liver fat, mitigate inflammation, and reverse fibrosis in NASH patients.
View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-present-at-the-jefferies-2019-london-healthcare-conference-300957394.html
Investor Contact: Christina Tartaglia, Stern Investor Relations, Inc., 212.362.1200, firstname.lastname@example.org or Media Contact: Marites Coulter, Verge Scientific Communication, 415.819.2214, email@example.com